307 Westlake Ave North
51 articles with Kineta Immuno-Oncology
Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and biodefense announced today that Kineta's management team has been invited to participate at H.C. Wainwright 21st Annual Global Investment Conference in New York, NY.
Shawn Iadonato, Kineta Chief Executive Officer, will provide a corporate overview on Thursday, August 15, 2019 at 2:00PM, Eastern Time.
Kineta Secures $1.8 Million Funding Boost from Wellcome Trust on Positive Phase 1a Clinical Study Results with LHF-535
Favorable overall safety, tolerability, and pharmacokinetic profile of LHF-535 for Lassa fever demonstrated in first-in-human study
LHF-535, Kineta's lead biodefense asset, is a novel once-daily oral antiviral drug currently being evaluated in Phase 1 safety trials in healthy volunteers.
Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies
Kineta Immuno-Oncology, LLC (KIO), a subsidiary of Kineta, Inc., today announced that it has entered into a strategic research collaboration with Pfizer Inc. (NYSE:PFE) to develop RIG-I agonist immunotherapies for the treatment of cancer.
Phase 1 study to assess the safety, tolerability and pharmacokinetic profile of LHF-535 in healthy volunteers
Kineta Chronic Pain signed an exclusive option and license deal with Genentech. The two companies will develop Kineta’s alpha9/alpha10 nicotinic acetylcholine receptor (nAChR) antagonists to treat chronic pain.
Collaboration to develop a first-in-class α9/α10 nicotinic acetylcholine receptor antagonist for the treatment of chronic pain
Small molecule RIG-I agonist induces innate immune responses, immunogenic tumor cell death and in vivo protective immune responses in a colon carcinoma model
Kineta Immuno-Oncology Announces Presentation on Novel RIG-I Agonists at Immuno-Oncology Frontiers World Conference
The conference takes place on January 22-25 at the Hyatt Regency Hotel in Miami, FL.
Kineta RLR Agonist Demonstrates Tumor Regression And An Adaptive Immune Response In Colon Carcinoma Model
Kineta Receives Wellcome Trust Award To Advance Novel Therapeutic For Lassa Fever Into Clinical Trials
Kineta Presents Promising New Data On Novel Lassa Fever Antiviral And Broad Spectrum Innate Immune Antivirals
Kineta Announces Promising New Data For KIN 1148 – A Novel Vaccine Adjuvant For Highly Pathogenic Flu